BioCentury
ARTICLE | Clinical News

Debio 0932: Phase I data

May 28, 2012 7:00 AM UTC

An open-label, dose-escalation, French Phase I trial in 51 evaluable patients with advanced solid tumors or lymphoma who were resistant to standard therapy showed that Debio 0932 given daily or every other day was generally well tolerated with no ocular or cardiac toxicity reported. Dose-limiting toxicities (DLTs) included febrile neutropenia at the once-daily 1,600 mg dose of Debio 0932 and diarrhea and asthenia at the 1,600 mg every other day dose. Additionally, rates of partial response and stable disease in patients receiving once-daily Debio 0932 (n=23) were 4% and 17%, respectively. Rates of partial response and stable disease in patients receiving Debio 0932 every other day (n=28) were 0% and 29%, respectively. Data will be presented at the American Society of Clinical Oncology meeting in Chicago in June. ...